PROTAC EGFR degrader 15

PROTAC EGFR degrader 15 is a Pomalidomide (HY-10984) -based Gefitinib (HY-50895) EGFR PROTAC degrader. PROTAC EGFR degrader 15 triggers EGFR degradation via ubiquitin-proteasome-dependent proteolysis and autophagy-lysosome activation pathways. PROTAC EGFR degrader 15 targets ETFA to enhance ATP production. PROTAC EGFR degrader 15 significantly suppresses tumor growth in a Gefitinib-acquired resistant HCC-827 xenograft model. PROTAC EGFR degrader 15 can be used for the study of non-small cell lung cancer (NSCLC) (Pink: EGFR ligand (HY-W109039) ; Blue: CRBN ligand (HY-10984) ; Black: Linker (HY-W679737) ) [1].

Product Specifications

UNSPSC

12352005

Target

ATP Synthase; EGFR; PROTACs

Related Pathways

JAK/STAT Signaling; Membrane Transporter/Ion Channel; PROTAC; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

97.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1)CCC(N2C(C(C(NC(CCCCCCCCCN3CCN(CCCOC4=CC(C(NC5=CC(Cl)=C(F)C=C5)=NC=N6)=C6C=C4OC)CC3)=O)=CC=C7)=C7C2=O)=O)C1=O

Molecular Formula

C45H52ClFN8O7

Molecular Weight

871.40

References & Citations

[1]Li L, et al. A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation. Bioorg Chem. 2025 Sep;164:108864.